Enzolytics Inc (ENZC)

[falon]

Yep Charles Cotropia dotted the I and crossing the T has brought this company a long way.

It has nothing to do with investors connecting DOTS.

You don't know JACK.

Nobody but the company does.

Will the company deliver the goods?

What will the results be?

We are encouraged by the positive feedback received from pharmaceutical companies who have acknowledged an interest in partnering upon achievement of defined milestones.

https://www.biospace.com/article/releases/enzolytics-reports-progress-on-its-multiple-therapeutics-platforms-and-initiatives/

Have those milestones be met?

"In the year ahead, Enzolytics will share additional plans regarding our technologies, planned partnerships, and projects, as well as achievements in each of our therapeutics platforms. We have full faith in our long-term vision and mission and are confident in our team's ability to achieve set goals."

https://www.theglobeandmail.com/investing/markets/stocks/ENZC/pressreleases/12620871/enzolytics-inc-announces-the-completion-of-the-2020-and-2021-audited-financials/

To accelerate and fully execute in the successful production of the multiple monoclonal antibodies the subject of the Company's intellectual property (specifically the numerous monoclonal antibodies (mAbs) targeting both human and animal viruses), the Company continuously engages with numerous entities to accomplish the successful goal of production, testing and delivery of successful therapeutics. Entities with whom the Company is working includes companies having:

Expertise in providing specialized peptides having precise amino acid sequences corresponding to the precise target sites on both the Coronavirus and HIV viruses which are then used in the Company's Texas lab against which mAbs are being produced. This strategy accelerates the production of the mAbs for further development.

Specialized cell soring technology that is complementary to the process used in the Company's lab to accelerate production of mAbs for advancing production.

Expertise in hybridoma production techniques for production of mAbs using hybridoma methodologies that are complementary to the process used in the Company's lab.

Animal trials centers, both in the U.S. and abroad, for preparation of animal trials.

Promotional entities with specialized expertise in targeting large funding sources for the purpose of raising the substantial funds needed for the production of the recombinant mAbs necessary for future trials and for conducting animal trials.

As to each of these entities, and those with whom the Company currently works on an ongoing basis, the Company has entered into NDA's (Nondisclosure Agreements) necessary to preserve and protect the intellectual property being discussed and exchanged between the parties. These contractual restrictions are critical for the Company and its partners. Maintenance of strict confidentiality is absolutely essential to preserving intellectual property rights (patent rights) which are now being sought and which will be sought in the future. Premature disclose of technical information may and generally does bar the right to successfully seek patent protection at a later date. The Company is not able to share specific information regarding arrangements regarding these NDA's

https://www.yahoo.com/now/enzolytics-announces-international-patent-office-103000840.html